Volunteers with conditions including depression, alcohol use disorder, and anorexia are being sought by Clerkenwell Health, to join its seminal clinical trials.
Emma Harvey is global head of medical affairs at F2G Ltd, a UK and Austria based biotech where she is responsible for the global medical and commercial strategies for a novel antifungal drug for serious systemic infections, in clinical development.
Patients with a rare and incurable blood cancer, associated with an overproduction of blood cells, will soon have access to a small molecule Novartis treatment.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for Pombliti + Opfolda, a two-component therapy to treat Pompe disease.
George Freeman MP, minister of state at the new Department for Science, Innovation and Technology, has praised a decade of growth at Discovery Park, the leading science and innovation campus in Sandwich, Kent.
The National Institute for Health and Care Excellence is weighing the viability of PD Neurotechnology’s PDMonitor system for Parkinson’s disease patients.
England's cost-effectiveness watchdog has recommended Eli Lilly’s Verzenios treatment as an option for adjuvant treatment of certain forms of breast cancer.
The institute and the research/support organization will collaborate on development of novel therapies aimed at treating the central nervous system disorder.
The Medicines and Healthcare Products Regulatory Agency has released proposals to bolster trials legislation, asking citizens for input on the suggestions.
Wasdell, a UK-based packaging and manufacturing provider in the UK, has opened a quality control laboratory in Dundalk to analyze products for its pharmaceutical clientele.
FarmaTrust is helping assemble a collective of public and private firms working on solutions for smart manufacturing and creating medicines of the future.
Intelligent Tissue Group has launched its Intelligent Clinical trials facility to help assess the effectiveness and safety of potential new treatments.
Year-on-year, the number of trials for advanced therapeutics has doubled, meaning that the UK now represents 12% of all global clinical trials in the area.
UK government signs freight capacity contracts to mitigate the risk that trade disruption will stop medicines from reaching patients related to a potential no-deal Brexit.
In response to the UK government’s publication of potential ramifications of a no-deal Brexit, the ABPI responded that the pharma industry needs more details on mitigation strategies.
Despite positive movement on the number of women serving on executive committees since 2018, the industry has seen a significant drop in positions governing profit and loss.
Highlighting the threat of AMR, the UK government has worked with the pharma industry to develop a new antibiotics payment model based on ‘usefulness’ to the NHS.
Wasdell Group has acquired specialist manufacturer and packager, Honeywood Limited in an aim to build its manufacturing and packaging capacity in the UK to support European supply chain.
Medicines Discovery Catapult launches a Virtual R&D Discovery Services platform made up of more than 20 CROs, which will help support small- to medium-sized companies deliver drug discovery projects.
The Anglo-Swedish company will cut the positions from the site by 2020, with a consultation on the process initiated yesterday, a workers union claimed.
The EMA announces further details on its move from current London headquarters to Amsterdam, which will begin on March 1 and see staff working in its new offices on March 11.
Novartis has announced plans to move its UK headquarters to an ‘emerging life sciences cluster’ in West London, 50 minutes’ drive from its current location in Surrey.
Rather than limit health care data collection, the industry should focus on ensuring those data sets are used ‘in the most appropriate way,’ according to Health iQ chief commercial officer.
As negotiations continue and discussions on ‘hard Brexit’ outcomes build, few have considered the impact on European industry, one organisation suggests.
With plans to “futureproof” its service offerings, Wasdell is investing €30m in a testing and distribution facility in Ireland – a growing market and gateway into Europe and North America, says CEO.
Preparations for an “unlikely” ‘no deal’ Brexit are underway in the UK, with the government instructing pharmaceutical companies to build their medicine reserves before March 2019.
A plan to attract advanced medicinal therapy manufacturing to the UK has emphasised the importance of the MHRA having a leading role in development of global regulatory standards.
Brexit will not stifle interest in the UK’s cell and gene therapy space, says the CGT Catapult which has reported a tenfold growth in investment since 2012 to £400m ($520m).
Brexit: Indian firms worried but Big Pharma and EMA remain positive for now
Brexit would create regulatory uncertainty, delay the launch of biosimilars and prevent NHS cost savings according to the newly founded British Biosimilars Association (BBA).
Celltrion has emphasised the savings Remsima ((inflizimab) could offer at a conference in Spain as partner Napp Pharmaceuticals prepares to extend the roll out of the Remicade biosimilar to the UK.
Despite a strong Q3, Icon has outlined plans for further cuts at its UK clinical pharmacology unit (CPU) as it rejigs its ‘weak’ early phase services business.